Immunocore Holdings plc
Immunocore Holdings plc (IMCR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IMCR · as of Sep 30, 2025
Ownership Breakdown
144
Institutional Holders
$1.79B
Total Inst. Value
▲ $288.00M vs Q2
50.83M
Shares Outstanding
freeFloat 99.04%
49.78M
13F Shares Held
▲ 1.42M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IMCR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 7.06M | 14.05% | 14.05% | $256.63B | Nov 14, 2025 | ▼ 3.8K |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 4.87M | 9.68% | 9.68% | $176.92B | Nov 14, 2025 | — held |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 4.78M | 9.51% | 9.51% | $173.69B | Nov 14, 2025 | ▲ 567.3K |
FMR LLC biological products, (no diagnostic substances) | 4.42M | 8.79% | 8.79% | $160.59B | Nov 13, 2025 | ▼ 435.4K |
PRIMECAP MANAGEMENT CO/CA/ biological products, (no diagnostic substances) | 3.75M | 7.47% | 7.47% | $136.40B | Nov 12, 2025 | ▼ 16.9K |
BELLEVUE GROUP AG biological products, (no diagnostic substances) | 2.80M | 5.56% | 5.56% | $101.61B | Nov 14, 2025 | ▲ 355.0K |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 2.32M | 4.62% | 4.62% | $84.38B | Nov 14, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.31M | 4.58% | 4.58% | $83.76B | Nov 14, 2025 | ▲ 200.0K |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 1.80M | 3.58% | 3.58% | $65.39B | Nov 14, 2025 | — held |
BVF INC/IL biological products, (no diagnostic substances) | 1.57M | 3.13% | 3.13% | $57.19B | Nov 14, 2025 | ▲ 550.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
25
Increased
+4.73M shares1
New Positions
first time holders17
Decreased
−1.80M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.93M
+4.73M / −1.80M
Net new holders
+9
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IMCR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Ratcliffe Peter John director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Peterson Kristine director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Pao William director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Kaul Siddharth director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Herbst Roy Steven director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Bell John Irving director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Coy Travis Alan Chief Financial Officer | Feb 17, 2026 | Award | 95,637 | $32.38 | $3.10M | 95.6K | Form 4 ↗ |
Coy Travis Alan Chief Financial Officer | Feb 17, 2026 | Award | 33,353 | — | — | 33.4K | Form 4 ↗ |
Jallal Bahija CHIEF EXECUTIVE OFFICER | Feb 17, 2026 | Award | 395,066 | $32.38 | $12.79M | 395.1K | Form 4 ↗ |
Jallal Bahija CHIEF EXECUTIVE OFFICER | Feb 17, 2026 | Award | 88,573 | — | — | 88.6K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Immunocore Holdings plc (IMCR) is primarily owned by institutional investors, who hold approximately 97.9% of total shares outstanding. Company insiders own approximately 0.96%, while retail and public investors account for the remaining 1.10%.
The largest institutional shareholder of Immunocore Holdings plc is T. ROWE PRICE INVESTMENT MANAGEMENT, INC., holding approximately 7.06 million shares — equal to 14.05% of outstanding shares — as of September 30, 2025.
A total of 144 institutional investors currently hold IMCR stock, with a combined institutional value of approximately $1.79 billion as of the most recent 13F filing period.
Frequently asked questions
IMCR ownershipImmunocore Holdings plc (IMCR) is primarily owned by institutional investors, who hold approximately 97.9% of shares. The largest shareholder is T. ROWE PRICE INVESTMENT MANAGEMENT, INC. with a 14.05% stake. Company insiders hold 0.96%. Data sourced from SEC Form 13F as of September 30, 2025.